Objectives: The aim of our study was to evaluate the clinicopathological features and prognostic factors of uterine carcinosarcoma. Patients and Methods: In this retrospective study, the clinical characteristics of 44 patients with uterine MMMT were evaluated. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. Results: Forty-four patients with uterine carcinosarcoma were referred to our unit between 1995 and 2015. Their median age was 66.5 years. All women underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Twenty-five percent had omental resection. Pelvic lymphadenectomy was performed in 18.2% of the cases. Twenty-six of the patients presented with stage I/II disease, 17 with advanced stages. In 20.5% of the cases there were metastases at diagnosis. Forty women received adjuvant chemotherapy, with complete remission in 67.9% of the cases. Recurrences were observed in 27.3% of the women. Disease-free and overall survival was 27 and 103 months, respectively. The FIGO stage, histological type, tumour size, chemotherapy regimen, pelvic lymphadenectomy, and myometrial invasion did not affect survival. Conclusions: Uterine MMMT is an aggressive tumour, often diagnosed at an advanced stage and with a high rate of metastases or recurrences. Because of its rarity, its management is controversial and fixed prognostic factors cannot be defined.

Keywords:
Uterine carcinosarcoma, Malignant mixed müllerian tumour, Prognostic factors
1.
Kanthan R, Senger JL: Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int 2011;2011:470795.
2.
Gonzalez Bosquet J, Terstriep SA, Cliby WA, et al: The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol 2010;116:419-423.
3.
Ramondetta LM, Burke TW, Jhingran A, et al: A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol 2003;90:529-536.
4.
de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H: Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol 2011;24:1368-1379.
5.
Arora P, Rao S, Khurana N, Talwar D, Tanwar R: Malignant mixed Müllerian tumor of broad ligament with synchronous ovarian and endometrial carcinoma: a rare association. J Cancer Res Ther 2011;7:88-91.
6.
Kuyumcuoğlu U, Kale A: Homologous type of malignant mixed Müllerian tumor of the uterus presenting as a cervical mass. J Chin Med Assoc 2009;72:533-535.
7.
Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA: Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653-1661.
8.
Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19.
9.
Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ: Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;15:2782-2786.
10.
Tavassoli FA, Devilee P (eds): Pathology and Genetics: Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. Lyon, IARC, 2003.
11.
Prat J: FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177-178.
12.
Doss LL, Llorens AS, Henriquez EM: Carcinosarcoma of the uterus: a 40-year experience from the state of Missouri. Gynecol Oncol 1984;18:43-53.
13.
Garg G, Kruger M, Christensen C, Deppe G, Toy EP: Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants. Int J Gynecol Cancer 2011;21:1606-1612.
14.
Lacour RA, Euscher E, Atkinson EN, et al: A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer 2011;21:517-522.
15.
El-Nashar SA, Mariani A: Uterine carcinosarcoma. Clin Obstet Gynecol 2011;54:292-304.
16.
Genever AV, Abdi S: Can MRI predict the diagnosis of endometrial carcinosarcoma. Clin Radiol 2011;66:621-624.
17.
Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT: Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 2010;20:888-894.
18.
Robinson-Bennett B, Belch RZ, Han AC: Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus. Int J Gynecol Cancer 2006;16:1354-1357.
19.
Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H: Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:630-634.
20.
Inthasorn P, Carter J, Valmadre S, Beale P, Russell P, Dalrymple C: Analysis of clinicopathologic factors in malignant mixed Müllerian tumors of the uterine corpus. Int J Gynecol Cancer 2002;12:348-353.
21.
Tanaka YO, Tsunoda H, Minami R, Yoshikawa H, Minami M: Carcinosarcoma of the uterus: MR findings. J Magn Reson Imaging 2008;28:434-439.
22.
Huang GS, Chiu LG, Gebb JS, et al: Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007;107:513-517.
23.
Suzuki A, Tahara H, Okamura H: Hysteroscopic diagnosis of malignant mixed müllerian tumour of the corpus uteri. Gynecol Oncol 1983;15:350-356.
24.
Shveiky D, Revel A, Rojansky N, Benshushan A, Shushan A: Diagnosis of malignant mesenchymal uterine tumors by hysteroscopic excisional biopsy. J Minim Invasive Gynecol 2005;12:29-33.
25.
Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ: Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-796.
26.
Vorgias G, Fotiou S: The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed müllerian tumours): a critical literature review. Arch Gynecol Obstet 2010;282:659-664.
27.
Nemani D, Mitra N, Guo M, Lin L: Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008;111:82-88.
28.
Bansal N, Herzog TJ, Seshan VE, et al: Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behaviour. Obstet Gynecol 2008;112:64-70.
29.
Wright JD, Seshan VE, Shah M, et al: The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008;199:536.e1-8.
30.
Niculescu M, Simionescu C, Novac L, Mogoantă L, Stănescu RM: The uterine carcinosarcoma - a case report. Rom J Morphol Embryol 2007;48:431-435.
31.
Magnani KK, Dubey S, Rai S: Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer. Indian J Pathol Microbiol 2010;53:886-887.
32.
Kernochan LE, Garcia RL: Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009;7:550-556; quiz 557.
33.
Markman M: Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed müllerian tumors): time for a re-appraisal? J Cancer Res Clin Oncol 2004;130:645-648.
34.
Menczer J, Levy T, Piura B, et al: A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005;97:166-170.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.